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While studies of the adaptor SH3BP2 have im-
plicated a role in receptor-mediated signaling
in mast cells and lymphocytes, they have failed
to identify its function or explain why SH3BP2
missense mutations cause bone loss and in-
flammation in patients with cherubism. We
demonstrate that Sh3bp2 ‘‘cherubism’’ mice
exhibit trabecular bone loss, TNF-a-dependent
systemic inflammation, and cortical bone ero-
sion. The mutant phenotype is lymphocyte in-
dependent and can be transferred to mice car-
rying wild-type Sh3bp2 alleles through mutant
fetal liver cells. Mutant myeloid cells show in-
creased responses to M-CSF and RANKL stim-
ulation, and, through mechanisms of increased
ERK 1/2 and SYK phosphorylation/activation,
they formmacrophages that express high levels
of TNF-a and osteoclasts that are unusually
large.M-CSF andRANKL stimulation ofmyeloid
cells that overexpress wild-type SH3BP2
results in similar large osteoclasts. This indi-
cates that the mutant phenotype reflects gain
of SH3BP2 function and suggests that SH3BP2
is a critical regulator of myeloid cell responses
to M-CSF and RANKL stimulation.
INTRODUCTION
Much progress has beenmade in characterizing cytokines
that regulate formation of multinucleated bone-resorbing
cells (osteoclasts) from mononuclear myeloid progenitors
(Ross and Teitelbaum, 2005; Tanaka et al., 2005). Much
is also known about downstream signaling pathways
and transcription factors (Mocsai et al., 2004; Takayanagiet al., 2002). Many of these pathways are important for
regulation of immune cells and othermyeloid-derived cells
and provide a basis for understanding how pathological
bone loss is associated with inflammation in rheumatic
diseases (Humphrey et al., 2005; Jimi and Ghosh, 2005;
Xing et al., 2005). However, except for studies of SHIP
phosphatase (Takeshita et al., 2002), little is known about
mechanisms that regulate responses of myeloid progeni-
tors to macrophage- and osteoclast-inducing signals.
Cherubism is a dominantly inherited syndrome charac-
terized by excessive bone resorption in the jaws and accu-
mulation of inflammatory/fibrous tissue in the lower face.
The pathological facial changes appear 2–4 years after
birth and regress after puberty. The association between
osteoclast-mediated bone resorption and inflammation
suggests an activation of processes controlling differenti-
ation of osteoclasts and inflammatory cells. The disorder
was mapped to chromosome 4p, and we identified amino
acid missense mutations in the SH3-binding protein
SH3BP2 in several cherubism families (Ueki et al., 2001).
Since the SH3BP2 gene is located within a region that
frequently is deleted in individuals with Wolf-Hirschhorn
syndrome and since patients with this syndrome do not
have cherubism (Zollino et al., 2000), it is unlikely that the
missensemutations in SH3BP2 represent loss-of-function
mutations (Ueki et al., 2001).
SH3BP2 was initially identified in a screen for proteins
that bind to the SH3 domain of the tyrosine kinase c-Abl
(Ren et al., 1993). Subsequently, it was also identified as
a SYK kinase, VAV, and as a 14-3-3 interacting protein
(Deckert et al., 1998; Foucault et al., 2003, 2005). Inter-
actions between SH3BP2 and a range of other proteins,
including ZAP70, Lyn kinase, PLCg, and LAT, have also
been described (Jevremovic et al., 2001; Maeno et al.,
2003; Qu et al., 2005; Sada et al., 2002). The binding of
SH3BP2 to several of these proteins requires phosphory-
lation of tyrosine and serine residues. SYK can phosphor-
ylate tyrosyl residues Y174, Y183, and Y446 (in the mouse
protein) within SH3BP2, and phosphorylation of at leastCell 128, 71–83, January 12, 2007 ª2007 Elsevier Inc. 71
one of these residues (Y446) has been suggested to be
critical for the ability of SH3BP2 to stimulate SYK tyrosine
phosphorylation (Maeno et al., 2003). Interaction of
SH3BP2 with 14-3-3 proteins requires phosphorylation
of S225 and S277 (in the mouse protein) in SH3BP2
(Foucault et al., 2003). The function of SH3BP2 is not
defined, but studies of T- and B-lymphoid cells suggest
that SH3BP2 may act as stimulator of NFAT-mediated
transcription and that this stimulatory activity is negatively
regulated by interaction of SH3BP2 with 14-3-3 proteins
(Deckert et al., 1998; Foucault et al., 2003). A recent study
of SH3BP2-deficient T and B cells suggests that SH3BP2
is particularly important for signaling in B cells (de la
Fuente et al., 2006).
To obtain insights into SH3BP2 function, we introduced
the most commonmutation found in cherubism, a proline-
to-arginine substitution (P418R in humans; P416R in
mice), into the mouse Sh3bp2 gene. Mutant mice are
osteoporotic with increased numbers of osteoclasts in
bone. In addition, homozygotes have massive infiltration
of macrophages into skeletal elements and internal
organs. The inflammatory component can be rescued by
eliminating TNF-a expression, and all aspects of the phe-
notype can be transferred through transfer of mutant fetal
liver cells into recipients carrying wild-typeSh3bp2 alleles.
The studies demonstrate that the adaptor SH3BP2 regu-
lates the bone marrow (BM) monocyte responses to
macrophage and osteoclast differentiation signals down-
stream of the receptors for macrophage colony-stimulat-
ing factor (M-CSF) and receptor activator of NF-kB ligand
(RANKL) through mechanisms that involve control of ERK
1/2 and SYK kinase activities.
RESULTS
Mouse Model for Cherubism
Embryonic stem cells were electroporated with a targeting
construct-encoding mutant SH3BP2 and used to gener-
ate chimeras (Figures S1A and S1B). Mice with germline
transmission of the targeted allele were crossed with
a CMV-cre mouse to excise the Neo cassette (Figures
S1A and S1C). Sequencing of cDNA synthesized with
mRNA from spleens of heterozygous knockin (KI) animals
confirmed heterozygosity for the P416R missense muta-
tion (Figure S1D). The mutation did not affect SH3BP2
protein expression in osteoclastic progenitors, in mature
osteoclasts generated in vitro by stimulation of BM cells
with M-CSF and RANKL, or in spleen cells (Figure S1E).
Mutant animals were born in the expected Mendelian
ratio. Heterozygotes showed no abnormalities by visual
inspection and had a normal life span. However, homozy-
gotes showed loss of survival with age (Figure S3A).
Bone Loss in SH3BP2 Mutants
MicroCT of calvarial and jaw bones in 10-week-old wild-
type and mutant littermates demonstrated reduced bone
volume in calvaria, loss of bone around teeth, and reduced
cortical bone thickness in jaws in homozygotes but not in72 Cell 128, 71–83, January 12, 2007 ª2007 Elsevier Inc.heterozygotes (Figures 1A and 1B). Histology showed no
difference between wild-type and heterozygous mice
(data not shown). In contrast, sections of homozygous
jaws showed large numbers of osteoclasts positive for
tartrate-resistant acid phosphatase (TRAP) along bone sur-
faces (Figure 2A). In long bones, microCT demonstrated
bone loss in both heterozygotes and homozygotes.
Three-dimensional reconstruction of trabecular bone
showed reduced trabecular bone volume and reduced
number of trabeculae (Figures 1C and 1D). However, only
asmall changewasseen in trabecular thickness (Figure1D).
Homozygous limb bones such as femoral bones
showed pitting of the cortical surface, particularly at the
distal end (Figure 1C). Histomorphometric analyses of
femoral trabecular bone from 10-week-old animals con-
firmed loss of bone in both hetero- and homozygotes. The
fraction of the total perimeter of bone profiles occupied
by osteoclasts and the number of osteoclasts were
increased (Figure 1E). The fraction of total perimeter of
bone profiles occupied by osteoblasts was increased as
well (Figure 1E), suggesting that bone loss in mutant
mice is associated with increased osteoclast and osteo-
blast activities.
P416R Mutation in SH3BP2 Causes Enhanced
Osteoclast Differentiation
Increased osteoclast numbers, particularly in homozy-
gotes (Figure 2A), led us to examine differentiation of oste-
oclastic progenitors frommutant and wild-type animals to
osteoclasts. When incubated with M-CSF and RANKL,
mutant BM cells differentiated into exceptionally large os-
teoclasts even at concentrations of RANKL (10 ng/ml) that
were insufficient to induce osteoclastic differentiation in
wild-type cultures (Figure 2B). Not only was the number
of osteoclasts higher in mutant cultures, but the number
of nuclei per osteoclast was also much higher (Figures
2C and 2D). Interestingly, the level of TRAP in conditioned
media was not different between heterozygous and
homozygous cultures (Figure 2E), and serum concentra-
tions of TRAP were elevated in hetero- and homozygotes
(Figure 2F). The resorptive activity of mutant osteoclasts
on dentin slices was elevated (Figure 2B). No differences
were seen in serum calcium or phosphate levels between
the three groups of mice (data not shown). As is consistent
with enhanced response to RANKL inmutant BM cells and
with formation of unusually large osteoclasts, transcripts
known to be strongly expressed in osteoclasts (Takaya-
nagi et al., 2002) were elevated in heterozygous mutant
cells after RANKL stimulation (Figure S2).
Systemic Inflammation in Homozygotes
Heterozygous mutants did not show swelling of facial soft
tissues and enlargement of lymph nodes as seen in pa-
tients with cherubism (Tiziani et al., 1999), but homozy-
gotes developed swollen eyelids starting about 6 weeks
after birth. Swelling of facial features remained in the few
homozygotes surviving until 30 weeks (Figures S3B and
S3C). Soft-tissue swelling was caused by the presence of
Figure 1. Bone Loss in SH3BP2 Mutants
(A) MicroCT images of calvarial bone (top),
mandibula (middle), and reconstructed man-
dibula (bottom) of male littermates. Arrows
indicate abnormal pits on mandibular surface.
(B) Mandibular width (n = 3), mandibular corti-
cal thickness (n = 6), and ratio of bone volume
to total volume of calvarial bone (n = 6).
(C) Three-dimensional microCT images of
femoral (top) and trabecular bone above the
distal femoral growth plate (bottom) in male
littermates.
(D) Bone volume/total volume, trabecular
number, and thickness above the distal femoral
growth plate (n = 6).
(E) Histomorphometry of osteoclast perimeter
per bone perimeter, osteoclast number per
bone surface, and osteoblast perimeter per
bone perimeter (n = 6). *p < 0.05. Error bars
represent a standard deviation (SD) of +1.inflammatory lesions. Such lesionswere present in cortical
regions of long bones (Figure 3A) and in maxilla, palate,
and mandible of homozygotes (Figures 3B and 3C). Eye-
lids were significantly thickened (Figure 3D), and the tis-
sues contained macrophages positive for markers F4/80
and CD11b (Figures 3A, 3C, and 3D). The infiltrates devel-
oped postnatally.
In some mice, similar infiltrates filled the synovial space
of large joints and penetrated through articular cartilage
and underlying bone into BM (Figure 3E). Bone-associated
infiltrates contained multinucleated TRAP-positive cells
(Figure 3F) similar to those typically seen in biopsies ofhuman cherubism lesions. X-rays of homozygous bones
showed cystic lesions (Figure 3G) similar to those seen
on X-rays of jaws from patients with cherubism. Macro-
phage-rich infiltrates containing TRAP-positive cells and
areas of fibrosis (Figure S4) were not limited to craniofacial
and limb bones and associated muscles and soft tissues.
Inflammatory lesionswith F4/80- andCD11b-positive cells
were seen in skin andmajor internal organs, including liver,
lung, and stomach (Figures 4A and 4B). The inflammation
first started in the liver and lungs at 1 week as small foci
containing neutrophils and macrophages; at 2 weeks, we
observed evidence of mild gastritis and more severe lungCell 128, 71–83, January 12, 2007 ª2007 Elsevier Inc. 73
Figure 2. Enhanced Osteoclast Differentiation in Mutant Tissue and BM Cells
(A) Hematoxylin-eosin (HE, left) staining and TRAP (right) staining of sections through maxillary first molar of 8-week-old mouse.
(B) Marrow cells cultured with M-CSF (50 ng/ml) and RANKL (10, 50, and 100 ng/ml) for 5 days followed by TRAP staining. Cultures on dentine slices
(Immunodiagnostic Systems Inc., Fountain Hills, AZ) for 14 days (50 ng/ml M-CSF and 50 ng/ml RANKL) stained with toluidine blue to visualize re-
sorption pits.
(C) TRAP-positive multinucleated cells on day 5 of culture (50 ng/ml M-CSF and 50 ng/ml RANKL).
(D) Number of nuclei per TRAP-positive cell on day 5 (50 ng/ml M-CSF and 50 ng/ml RANKL).
(E) TRAP 5b in culture supernatants on day 5.
(F) TRAP 5b in serum of 6- to 10-week-old mice (n = 12–15). Horizontal red bars indicate average values. *p < 0.05. Error bars represent SD of ± 1.and liver inflammation. At 7 weeks, the process appeared
in the spine (data not shown). No evidence of bacterial or
fungal infection was seen (data not shown).
Increased Levels of TNF-a in Homozygotes
Next, we measured TNF-a serum levels. TNF-a could not
be detected in sera of wild-type and heterozygous
mutants, but homozygous sera contained TNF-a levels
ranging from 200 to 700 pg/ml (Figure 4C). Furthermore,
FACS analysis of F4/80-gated peritoneal macrophages74 Cell 128, 71–83, January 12, 2007 ª2007 Elsevier Inc.isolated from 10-week-old mice demonstrated dramatic
increase in the proportion of TNF-a-expressing cells in
homozygous mutants (Figure 4D). Increased production
of TNF-a by mutant macrophages was also evident
when peritoneal macrophages were cultured as adherent
cells (Figure 4E). Under these conditions, only low levels
of TNF-a could be detected in culture supernatants of
heterozygous cells after 16 hr. However, after 48 hr, the
same high levels of TNF-a were detected in both hetero-
and homozygous cultures.
Figure 3. Macrophage-Rich Inflamma-
tory Infiltrates in Homozygous Tissues
(A) HE staining of humerus of 8-week-old wild-
type and homozygous mutant (top). Inflamma-
tory infiltrate in cortical bone is indicated by
arrow. MicroCT images of cross-sections of
femoral bone from 10-week-old males (mid-
dle). Staining of inflammatory lesion at perios-
teum of 10-week-old homozygote with F4/80
antibodies and CD11b antibodies (bottom).
(B) HE staining of frontal section of facial
tissues from 10-week-old wild-type and homo-
zygous mutants. Arrows indicate inflammatory
infiltrates in zygomatic bone and periodontal
ligament of maxillary first molar (inset) in homo-
zygous mutant.
(C) HE staining of palate of 10-week-old wild-
type and homozygous mice (top). Staining of
inflammatory lesion in palate from 10-week-
old homozygous mutant with F4/80 antibodies
and CD11b antibodies (middle). HE staining of
mandibula from 10-week-old mouse (bottom).
(D) HE staining of eyelid from 10-week-oldwild-
type and homozygous mice (left). F4/80- and
CD11b-rich inflammatory infiltrates in eyelid
from 10-week-old homozygous mutant (right).
(E) HE staining of 20-week-old homozygous
knee joint; note destruction of articular carti-
lage and subchondral bone.
(F) TRAP-positive multinucleated cells (arrow
heads) in inflammatory infiltrates in distal
humerus.
(G) X-ray images of ankle regions of 10-week-
old homozygous and wild-type littermates.
Arrow indicates cystic lesions at distal tibia.To find out whether increased production of TNF-a
was the result of transcriptional or posttranscriptional
mechanisms, we measured TNF-a transcript levels by
real-time PCR in BM-derived, M-CSF-dependent macro-
phages. Following incubation in M-CSF-free media,
restimulation of M-CSF-dependent macrophages with
M-CSF led to a large increase in TNF-a transcripts in
mutant cells (Figure 4F). This increase could be inhibited
by MEK inhibitor U0126. The inhibitory effect of U0126
was also seen in assays of TNF-a protein in culture super-
natants (Figure 4G), suggesting that the enhanced
production of TNF-a in mutant cells is based on a tran-
scriptional mechanism. To identify which signaling path-
way downstream of the M-CSF receptor is mediating
the enhanced TNF-a transcription in mutant BM cells,
we compared the effects of U0126 and an NF-kB inhibi-
tor, a cell-permeable NEMO-binding domain peptide, on
TNF-a protein levels in culture media of M-CSF-depen-
dent, BM-derived macrophages. While U0126 completely
inhibited TNF-a production in mutant cells, the NEMO-binding domain peptide had a small stimulatory effect
(Figure 4H). The NEMO-binding domain peptide has been
shown to inhibit NF-kB signaling in mouse BM-derived
osteoclast progenitors and to block osteoclast formation
(Jimi et al., 2004); control experiments (data not shown)
showed that at the concentration used for the TNF-a ex-
periment, the peptide completely inhibited M-CSF- and
RANKL-induced formation of osteoclasts in wild-type and
mutant marrow cultures. As expected (Jimi et al., 2004),
a mutant peptide had no activity (data not shown). There-
fore, signaling through NF-kB does not contribute to
increased TNF-a production by mutant macrophages.
P416R Mutation Enhances M-CSF-Dependent ERK
1/2 Phosphorylation
The above results indicate that the cherubism mutation
in SH3BP2 enhances the response of macrophages to
M-CSF by affecting a U0126-sensitive pathway regulat-
ing TNF-a transcription. To better define signaling steps
affected by mutant SH3BP2, BM cells were incubatedCell 128, 71–83, January 12, 2007 ª2007 Elsevier Inc. 75
Figure 4. Systemic Inflammation in Internal Organs and Elevated TNF-a Expression in Mutant Macrophages
(A) HE staining of liver (top; 10 weeks), lung (middle; 10 weeks), and stomach (bottom; 15 weeks) of wild-type and homozygous littermates.
(B) Staining of inflammatory lesions in liver, lung, and stomach (from top to bottom) of 10-week-old homozygotes with F4/80 antibodies and CD11b
antibodies.
(C) Serum TNF-a concentration in 10- to 12-week-old wild-type and mutant mice (n = 12–15). Horizontal red bar indicates average value.
(D) FACS analysis of TNF-a in peritoneal macrophages.
(E) TNF-a concentration in culture supernatant of peritoneal macrophages.
(F) Real-time PCR analysis of TNF-a transcripts in BM-derived, M-CSF-dependent macrophages in the absence and presence of U0126.
(G) TNF-a levels in macrophage culture supernatants before and after 2 and 24 hr (H) of M-CSF stimulation in the absence and presence of U0126.
TNF-a levels normalized to protein amounts.
(H) TNF-a levels in culture supernatants 36 hr (H) after M-CSF stimulation in the absence and presence of U0126 or NEMO-binding domain (NBD)
peptide. Error bars represent SD of +1.with M-CSF, starved with 0.1% FBS, and restimulated
with M-CSF. No difference in the total levels and degree
of phosphorylation of several signaling components was
seenwhen comparing wild-type and heterozygousmutant
cells (Figure 5A). In contrast, homozygous cells showed76 Cell 128, 71–83, January 12, 2007 ª2007 Elsevier Inc.increased levels as well as sustained phosphorylation of
ERK 1/2 and increased levels of p38 and IkBa (Figure 5A).
Increased and sustained levels of phosphorylated ERK1/2
in homozygousmutant cells were also seenwhenBMcells
were grownwithM-CSF, starvedwith 1 ng/mlM-CSF, and
Figure 5. Sustained ERK Phosphoryla-
tion in Mutant Macrophages and
Elevated SYK Y346 Phosphorylation in
Mutant Osteoclasts
(A) Elevated levels of ERK, p38, and IkBa as
well as sustained ERK, p38, and Akt phos-
phorylation in BM-derived, M-CSF-dependent
macrophages following M-CSF restimulation.
(B) Increased and sustained ERK 1/2 phos-
phorylation in BM-derived macrophages fol-
lowing stimulation with RANKL and 1 ng/ml
M-CSF.
(C) Increased phosphorylation at SYK Y346 in
BM cells cultured with M-CSF for 48 hr and
stimulated further with M-CSF and RANKL.
(D) Increased phosphorylation of SYK Y346
following overexpression of wild-type and mu-
tant SH3BP2 in wild-type myeloid cells as well
as stimulation with M-CSF and RANKL.
(E) Overexpression of wild-type and mutant
SH3BP2 enhances M-CSF/RANKL-induced
osteoclastogenesis in wild-type myeloid cells.
(F) Effects of SYK kinase inhibitor on multinu-
cleation of TRAP-positive cells in wild-type
and heterozygous BM cultures. Panels at
bottom show wild-type and mutant cultures at
higher magnification.
(G) Histograms showing the relative number
(in percent of control numbers) of TRAP-
positive osteoclasts in osteoclastogenic cul-
tures of wild-type and KI/+ myeloid cells in
the presence and absence of SYK kinase inhib-
itor. Cell counts were determined by counting
5 areas in each of 5 wells in 48-well plates.
*p < 0.05; error bars represent SD of +1.then stimulatedwithRANKL (Figure 5B). High levels of ERK
1/2 phosphorylation were seen even after 6 hr in the pres-
ence of only 1 ng/ml ofM-CSF, indicating that homozygos-
ity for the cherubism mutation increases the response of
myeloid cells to M-CSF.
P416R Mutation Causes Gain of SH3BP2 Function
and Affects a SYK-Kinase-Dependent Step
Next we determined expression and phosphorylation
levels of intracellular signaling components in differentiat-
ing osteoclasts. Cell extracts were prepared at different
time points following addition of RANKL to cultures of
BM-derived cells that had been ‘‘primed’’ by incubation
with M-CSF. No significant differences were seen
between wild-type and mutant cells either at protein or
phosphorylation levels for a number of signaling interme-
diates and transcription factors, except that the level of
phosphorylation at SYK Y346 was increased in both
heterozygous and homozygous cells compared with
wild-type cells (Figure 5C). No differences were seen
with antibodies against SYK phosphotyrosines 317 and
519/520 or against SYK protein. Overexpression of both
wild-type and mutant SH3BP2 in wild-type, BM-derivedosteoclastic progenitors combined with stimulation with
M-CSF and RANKL resulted in enhanced levels of SYK
Y346 phosphorylation (Figure 5D) as well as the formation
of osteoclasts with large numbers of nuclei per osteoclast
(Figure 5E) compared to control cells infected with virus-
containing empty vector. Since overexpression of wild-
type SH3BP2 in M-CSF- and RANKL-stimulated myeloid
cell cultures results in enhanced SYK phosphorylation
and osteoclastogenesis similar to what is seen with
M-CSF- and RANKL-stimulated heterozygous and homo-
zygous mutant myeloid cells (Figures 5C–5E), the results
suggest that the P416R mutation is indeed a gain-of-
function mutation.
To find out whether the increased phosphorylation at
Y346 is associated with increased SYK kinase activity,
we examined the effects of inhibiting SYK activity in differ-
entiating osteoclasts. Addition of a kinase inhibitor at
a concentration of 10 mM reduced the number of TRAP-
positive multinucleated cells in wild-type marrow cultures
to 4%. In contrast, it was reduced to 36% in heterozygous
cultures (Figures 5F and 5G). This suggests that heterozy-
gous cells have higher levels of SYK activity thanwild-type
cells.Cell 128, 71–83, January 12, 2007 ª2007 Elsevier Inc. 77
Figure 6. Phenotypic Abnormalities in
Homozygous Mutants are Myeloid Cell
Dependent
(A) HE staining of wild-type and mutant lymph
nodes (top) and spleens (bottom; 10 weeks).
(B) Staining of mutant lymph nodes with F4/80
antibodies and CD11b antibodies.
(C) CD11b-positive cells in wild-type and
mutant BM (10 weeks).
(D) Decreased bone mineral density in
10-week-old KI/KI Rag1+/+ and KI/KI Rag1/
mice and enhanced BM-derived osteoclast for-
mation from KI/KI Rag1+/+ and KI/KI Rag1/
mice following M-CSF/RANKL stimulation.
(E) HE staining of spleen and liver (top), lung
(middle), and periosteum (bottom) of 10-
week-old KI/KI Rag1/ mice.
(F) High-serum TNF-a concentration of 10-
week-old KI/KI Rag1/ mice. Average is indi-
cated by red bar.
(G) MicroCT images of distal femurs from
10-week-old KI/KI +/+ and KI/KI op/op litter-
mates (top). HE staining of stomach (middle)
and lymph node (bottom) of KI/KI +/+ and
KI/KI op/op mice.
(H) Partial rescue of inflammation in liver of
KI/KI op/op mouse.
(I) Serum TNF-a levels inKI/KI op/opmice com-
pared with wild-type, op/op, KI/KI, and KI/KI
op/+ mice. Wild-type mice included mice that
were heterozygous for the op allele (+/*). Aver-
age values are indicated by red bars. *p < 0.05;
error bars represent SD of +1.Enlarged Lymph Nodes and Increased Levels of
CD11b-Positive Cells in Homozygous Spleen and BM
Enlarged cervical lymph nodes are a feature of human
cherubism (Tiziani et al., 1999). In mutant mice, no signifi-
cant enlargement of lymph nodes was observed in hetero-
zygotes. However, lymph nodes were noticeably larger in
homozygotes, and histological analysis demonstrated
increased medullary regions of lymph nodes and red pulp
in spleen (Figure 6A). These regions were strongly positive
with F4/80 and CD11b staining (Figure 6B). FACS analysis
of lymph node cells demonstrated a higher proportion of B
cells in mutant nodes. Wild-type lymphocytes contained
24.9% CD19-positive cells compared with 48.8% CD19-
positive cells fromhomozygotes. In contrast, no significant
differencewas foundbetweenwild-typeandheterozygous
cell populations. FACS analysis of myeloid-gated spleen
cells from 6-week-old animals showed 56.6% CD11b-
positive cells in homozygotes compared to 35.8%CD11b-
positive cells in wild-type mice. FACS analysis of BM from
homozygotes also demonstrated increased proportions
of CD11b-positive cells, but no difference was seen
when comparing heterozygous andwild-typemarrow (Fig-78 Cell 128, 71–83, January 12, 2007 ª2007 Elsevier Inc.ure 6C). No difference was seen in CD4/CD8 T cell sub-
populations in thymus between wild-type and homo-
zygous animals (data not shown).
Since SH3BP2 has been implicated as a positive regu-
latory adaptor in T cells (Deckert et al., 1998), B cells (Fou-
cault et al., 2005), and NK cells (Jevremovic et al., 2001)
and because lymphocytes are known to produce factors
that induce osteoclastic differentiation and promote in-
flammation (Nathan, 2002), the above results raised the
possibility that the phenotype in mutant mice may, at least
in part, be caused by SH3BP2-dependent abnormal lym-
phocyte signaling. To examine this possibility, SH3BP2
mutant mice were crossed with RAG1-deficient mice.
Mice that were homozygous for the Sh3bp2 mutant allele
and null for Rag1 exhibited no improvement in the degree
of bone loss when compared with SH3BP2 mutants (Fig-
ure 6D). Furthermore, BM cells stimulated with M-CSF
and RANKL showed enhanced formation of large osteo-
clasts similar to that in marrow cultures from mice carry-
ing only mutant Sh3bp2 alleles (Figure 6D). Also, double
mutants contained the same macrophage-rich inflamma-
tory infiltrates in internal organs and periosteal regions
Figure 7. Cherubism Is TNF-aDependent
Hematopoietic Disorder
(A) No macrophage infiltration in KI/KI Tnf-a/
tissues (from top: palate, liver, lung, stomach,
and lymph node; 10 weeks).
(B) Rescue of cortical bone loss in KI/KI Tnf-
a/ mice (10 weeks); *p < 0.05 and n = 3–6.
(C) TRAP staining of BM cells from wild-type
and SH3BP2 TNF-a double mutants after
5 days of culture with M-CSF (50 ng/ml) and
RANKL (50 ng/ml).
(D) Serum TNF-a levels in irradiated recipients
8 weeks after transplantation of fetal liver cells.
Average is indicated by red bar.
(E) MicroCT images of humerus (top) showing
osteoporosis in KI/KI fetal liver cell recipients
13 weeks after transplantation and increased
osteoclastogenesis (bottom) in vitro.
(F) HE staining of liver (top), stomach (middle),
and lymph node (bottom) from recipients
receiving wild-type (left) and KI/KI (right) fetal
liver cells (13 weeks after transplantation).
(G) Proposed pathogenesis of cherubism.
Mutant SH3BP2 increases responses of mye-
loid cells toM-CSF andRANKL.When exposed
to M-CSF, the cells differentiate to hyperactive
macrophages with enhanced production of
TNF-a. When stimulated with M-CSF and
RANKL, they differentiate and fuse to large
osteoclasts with high bone-resorbing activity.
Based on the report by Kitaura et al. (2005),
TNF-a may stimulate M-CSF and RANKL
production by stromal cells, thereby further
enhancing macrophage and osteoclast forma-
tion. TNF-a-mediated inflammation and osteo-
clast-mediated bone loss are the pathological
hallmarks of cherubism.as were seen in homozygous SH3BP2 single mutants
(Figure 6E). Finally, double mutants contained elevated
serum levels of TNF-a (Figure 6F).
Cherubism Is a TNF-a-Dependent Hematopoietic
Disorder
To determine the contribution of enhanced M-CSF-medi-
ated signaling to theSh3bp2mutant phenotype in vivo, we
crossed Sh3bp2mutants with op/opmice lackingM-CSF.
In KI/KI op/op mice, cortical bone resorption and inflam-
mation of the stomachmucosawere practically eliminated
(Figure 6G), and inflammation of the liver was greatly
reduced (Figure 6H). However, serum TNF-a levels were
still higher than in wild-type mice at 10 weeks (Figure 6I),
and macrophage numbers were still increased in lymph
nodes (Figure 6G).
To determine whether TNF-a is crucial for the homozy-
gous phenotype, we crossed Sh3bp2 mutants with Tnf-a
null mice. Absence of TNF-a resulted in rescue of lymph
node abnormalities and systemic inflammation, and it pre-
vented trabecular and cortical bone loss (Figures 7A and
7B). However, BM cells from double mutants showedthe same enhanced response to M-CSF and RANKL
stimulation as heterozygous and homozygous SH3BP2
mutant cultures did (Figure 7C).
The enhancedBMcell responses to cytokines that stim-
ulate differentiation to osteoclasts as well as the large
numbers ofmacrophages in skeletal elements and internal
organs of homozygotes suggest that cherubism is a hema-
topoietic disorder. To find out whether this is indeed the
case, we transplanted fetal liver cells from wild-type and
Sh3bp2mutantmice intoRag1 null recipients. Eightweeks
after injection of fetal liver cells, the recipients receiving
liver cells from homozygous Sh3bp2 mutants had high
serum levels of TNF-a (Figure 7D), exhibited severe osteo-
porosis (Figure 7E), showed formation of abnormally large
TRAP-positive osteoclasts in BM cultures stimulated by
M-CSF and RANKL (Figure 7E), had macrophage-rich in-
filtrates in internal organs, and showed abnormal lymph
nodes similar to those seen in homozygous Sh3bp2 mu-
tant mice (Figure 7F). In contrast, TNF-a could not be de-
tected in sera from recipients receiving fetal liver cells from
wild-typeorheterozygousSh3bp2mutantmice (Figure7D),
and macrophage-rich cellular infiltrates were not seen.Cell 128, 71–83, January 12, 2007 ª2007 Elsevier Inc. 79
DISCUSSION
Mutant SH3BP2 BM Cells Exhibit Enhanced
Responses to M-CSF and RANKL
Our data show that a cherubismmutation in SH3BP2 stim-
ulates signaling downstream of receptors for both M-CSF
and RANKL. Overexpression of wild-type SH3BP2 in BM
cells increased SYK Y346 phosphorylation and enhanced
formation of large osteoclasts in vitro similar to what is
seen with mutant cells (Figures 5D and 5E). The effect of
the SH3BP2 mutation is therefore a gain-of-function
effect. In SH3BP2-deficient mice, only subtle impairment
of several B cell processes has been noted (de la Fuente
et al., 2006). Therefore, SH3BP2 is unlikely to be important
for setting the basic response threshold to incoming
signals in wild-type myeloid cells but may serve to
enhance responses under conditions of increased macro-
phage and osteoclast differentiation.
SH3BP2 and SYK Kinase
How mutant SH3BP2 causes enhanced phosphorylation
of SYK Y346 is not clear. SH3BP2 can bind to SYK via
its C-terminal SH2 domain, and the two proteins can co-
operatively activate NFAT activity in T cells (Deckert
et al., 1998). Furthermore, it has been reported that
SH3BP2 can stimulate NFAT-reporter activity in B cells
in cooperation with the SYK kinase substrate VAV
(Foucault et al., 2005). Thus, SH3BP2 may function within
a SYK-containing complex in osteoclastic progenitors,
and cherubism mutations, which are all located in a small
region upstream of the SH2 domain (Ueki et al., 2001),
may enhance the ability of SH3BP2 to stimulate phos-
phorylation of SYK Y346. In preliminary experiments
(data not shown), we have found that, when overex-
pressed with SYK in 293T cells, SH3BP2 can be immunoi-
solated as a component of a SYK-containing complex.
Further studies are needed to determine the molecular
composition of this complex and the mechanism by which
SH3BP2 regulates phosphorylation of SYK Y346.
The similarity between heterozygous and homozygous
osteoclast cultures (Figure 2B) combined with enhanced
SYK Y346 phosphorylation (Figure 5C) and evidence of in-
creased SYK activity (Figure 5G) suggests that enhanced
osteoclastogenesis in cherubism is primarily an effect of
SYK activation (Figure 7G). This is consistent both with
reports that SYK-deficient, BM-derived cells exhibit
impaired multinucleation and spreading in the presence
of M-CSF and RANKL (Faccio et al., 2003; Mocsai et al.,
2004) as well as with the role of SYK kinase as an
upstream regulator of the guanine nucleotide-exchange
protein VAV3 in osteoclasts (Faccio et al., 2005). Phos-
phorylation of SYK at Y342 and Y346 generates a docking
site for PLCg and VAV in B cells, and this interaction with
PLCg allows SYK to stimulate PI3K-independent Ca2+
signaling and activation of NFAT (Deckert et al., 1996;
Hong et al., 2002; Law et al., 1996). Given the role of
NFATc1 in osteoclastogenesis (Takayanagi et al., 2002),
one may therefore expect enhanced levels of transcripts80 Cell 128, 71–83, January 12, 2007 ª2007 Elsevier Inc.of several NFAT target genes in mutant osteoclasts
consistent with the high levels of transcripts seen in het-
erozygous osteoclast cultures (Figure S2).
SH3BP2 and Macrophage Activation
The enhanced response to osteoclast-inducing signals
in vitro is not significantly different with myeloid cells
from heterozygous and homozygous mice. However, the
in vivo phenotypes are dramatically different. This in vivo
difference is clearly driven by increased expression of
TNF-a since high serum levels of TNF-a are only seen in
homozygous mutants (Figure 4C), and the loss of cortical
bone, inflammatory tissue infiltration, and lymph node
abnormalities can be eliminated by crossing cherubism
mice with TNF-a-deficient mice (Figures 7A and 7B).
TNF-a induces RANKL expression in BM stromal cells
and stimulates formation of CD11b-positive osteoclastic
progenitors (Kitaura et al., 2005; Yao et al., 2006). Activa-
tion of ERK kinase is known to result in induction of TNF-
a (Dumitru et al., 2000). Sustained phosphorylation of ERK
1/2 in mutant SH3BP2 cells suggests that induction of
TNF-a may be a consequence of enhanced ERK 1/2 sig-
naling (Figure 7G). Since TNF-a stimulation can also result
in ERK 1/2 activation (Eliopoulos et al., 2006), both high
protein levels of ERK 1/2 and sustained phosphorylation
in homozygous marrow cells exposed to M-CSF are likely
maintained through a positive autocrine feedback loop.
The enhanced production of TNF-a in M-CSF-stimulated
myeloid cells is associated with increased levels of TNF-
a transcripts. The TNF-a gene promoter is known to con-
tain several NF-kB-like motifs, and these are thought to
play a prominent role in TNF-a transcription (Shakhov
et al., 1990) in primary macrophages. However, a cell-per-
meable NEMO-binding domain peptide did not inhibit
TNF-a production in wild-type and mutant BM cells. In
contrast, the MEK inhibitor U0126 had a dramatic effect.
Therefore, we conclude that enhanced TNF-a transcrip-
tion and protein production in mutant cells are primarily
consequences of enhanced signaling through a U0126-
sensitive pathway; this is consistent with sustained phos-
phorylation of ERK 1/2 in mutant cells (Figures 5A and 5B).
The basis for ERK 1/2 activation in homozygous mutant
cells is not known. Since SH3BP2 can interact with 14-3-3
proteins, which are known to bind to the kinase suppres-
sor of Ras (Kolch, 2005), we have considered the possibil-
ity that the cherubism mutation may affect the binding of
SH3BP2 to 14-3-3 proteins, resulting in enhanced ERK
1/2 activation. In fact, Miah et al. (2004) reported that mu-
tant SH3BP2 fails to bind to 14-3-3 proteins in COS-7
cells. However, in preliminary experiments, we have found
no difference in the interaction betweenwild-type andmu-
tant SH3BP2 and 14-3-3t in 293T cells (data not shown).
Cherubism Is a Myeloid Cell-Dependent Disorder
The results of fetal liver cell transplantation and the
crosses of Sh3bp2 homozygous mutants with Rag1/
mice indicate that the cherubism phenotype is primarily
a consequence of abnormal myeloid cell function. At
present, we cannot rule out the possibility that the
SH3BP2 mutation has a direct effect on osteoblasts; nev-
ertheless, the net effect is loss of bone in both heterozy-
gous and homozygous mutants. The effects of TNF-a in
homozygotes are consistent with what is known about
this cytokine in the context of other forms of inflammatory
bone loss in humans and mice. At low concentrations,
TNF-a stimulates M-CSF production by BM stromal cells,
and this in turn results in an increase in osteoclastic pro-
genitors in BM (Kitaura et al., 2005). This is consistent
with our finding of increased numbers of CD11b-positive
cells in homozygous marrow. Reduced TNF-a serum
levels and reduced inflammation in KI/KI mutants follow-
ing crossing with op/op mice are consistent with the role
of M-CSF as inducer of TNF-a in macrophages (Chitu
and Stanley, 2005) andwith the finding that injection of an-
tibodies against the M-CSF receptor prevents TNF-a-in-
duced osteolysis in mice (Kitaura et al., 2005). Interest-
ingly, macrophage numbers in lymph nodes were not
significantly reduced in KI/KI op/op mice. Also, although
TNF-a serum levels were reduced in double mutants,
they were still higher than in wild-typemice, and infiltration
of macrophages into liver was reduced but not eliminated
(Figures 6H and 6I). Thus, M-CSF-independent pathways
of macrophage differentiation and TNF-a production ex-
ist. This is consistent with what is known about lymph
node macrophages and postnatal BM recovery of macro-
phages in op/op mice (Cecchini et al., 1994; Niida et al.,
2005).
To what extent do the abnormalities in mice reflect what
happens in humans with cherubism? The human disease
starts after birth and results in jaw bone loss as well as
soft tissue inflammation/swelling. However, in spite of
differences in the disease process in humans and mice,
we suggest that the underlyingmechanisms are quite sim-
ilar. Heterozygous cherubism mutations in humans may
well result in increased osteoclastogenesis that is partially
compensated for by increased osteoblast activity as in
mice. The postnatal inflammatory bone loss in jaws may
be due to local induction of the process that in homozy-
gous mutant mice appears as systemic TNF-a-driven os-
teolysis and macrophage infiltration. Once initiated, the
process may continue to recruit BM-derived monocytes
into the jaws. If correct, the results of this study suggest
that anti-TNF-a therapy, which is currently in use for other
disorders of inflammatory bone loss such as rheumatoid
arthritis (Smolen and Steiner, 2003), may well be effective
in treatment of cherubism.
EXPERIMENTAL PROCEDURES
Mice
To introduce a proline-to-arginine (P416R) mutation into exon 9 of
murine Sh3bp2, a targeting construct was made and electroporated
into embryonic stem (ES) cells (J1; for details, see Supplemental
Data). After screening, four selected ES clones were used for genera-
tion of chimeras. After confirmation of germline transmission, mice
were crossed with a cre-deleter strain to remove the Neo cassette inthe Sh3bp2 gene. All animals in the study were housed in pathogen-
free facilities and monitored carefully.
For genotyping, PCRwith primers fromwithin intron 8 of the Sh3bp2
gene was used. For sequencing, the Sh3bp2 gene mRNA was isolated
from spleens of 10-week-old animals.
Rag1/ and op/opmice were purchased from Jackson Laboratory
and bred with KI/+ mice. KI/+ Rag1+/, KI/+ Tnf-a+/, or KI/+ Csf1op/+
mice were crossed to generate KI/KI Rag1/, KI/KI Tnf-a/, or KI/KI
op/op double mutants. Double-mutant mice were analyzed at
10 weeks of age.
MicroCT
MicroCT (mCT20; Scano Medical AG, Bassersdorf, Switzerland)
was performed on bone specimens using groups of 6 wild-type
(+/+), 6 heterozygous (KI/+), and 6 homozygous (KI/KI) 10-week-old
mice. MicroCT was also performed on femoral specimens of KI/KI
op/op and KI/KI TNF-a/ mutants as well as on humerus of Rag1/
recipients of KI/KI fetal liver cells (for details, see Supplemental Data).
Data were analyzed for statistical significance using Student’s t test
or one-way ANOVA with Bonferroni correction.
Histomorphometry
Femurs were fixed in 70% ethanol, dehydrated in ethanol, cleared in
xylene, and embedded in methyl methacrylate. Five micrometer longi-
tudinal serial sections were cut on a Reichert-Jung PolyCut S micro-
tome (Reichert-Jung, Germany) with a D profile knife (Delaware
Diamond Knives Corp., Wilmington, DE). Sections taken from the
middle of femur were stained with modified Masson Trichrome stain.
Osteoblasts were identified as cuboidal cells lining trabecular bone.
Osteoclasts were identified as multinucleated TRAP-positive cells on
the bone surface. For further details, see Supplemental Data.
Histology
Tissues were fixed in phosphate-buffered saline (pH 7.4) containing
4% paraformaldehyde, decalcified by incubation in 0.5 M EDTA (pH
7.2), and embedded in paraffin. Six micrometer sections were cut
(Microm HM 355, Richard-Allan Scientific, Kalamazoo, MI) and dried
on Superfrost Plus slides (VWR International, West Chester, PA). Sec-
tions were used for hematoxylin-eosin (HE; Richard-Allan Scientific,
Kalamazoo, MI), modified Masson Trichrome, and TRAP staining.
For TRAP staining, a kit from Sigma-Aldrich (387-A, St. Louis, MO)
was used.
Immunohistochemistry
Tissues were quickly frozen in OCT compound (Sakura, Japan) in an
ethanol/dry ice bath. Sixmicrometer sections were cut (CM3000, Leica
Instruments, Nussloch, Germany) and dried at room temperature on
Superfrost Plus slides. Just before staining, sections were fixed with
acetone for 10 min. Vectastain Elite ABC kit (Vector Laboratories
Inc., Burlingame, CA) was used for HRP-based immunohistochemis-
try. CD11b (clone: M1/70) and F4/80 (clone: CI: A3-1) antibodies
were purchased from BD Biosciences Pharmingen (San Diego, CA)
and Caltag (Burlingame, CA), respectively. Negative controls included
sections incubated without the primary antibodies.
TRAP 5b and TNF-a ELISA
TRAP 5b and TNF-a in serum and culture media were measured with
a TRAP assay kit (SBA Sciences, Turku, Finland) and DuoSet ELISA
Development kit (R&D, Minneapolis, MN), respectively.
BM Cultures
BM cells from tibia and femur of 6- to 10-week-old mice were flushed
out with ice-cold a-MEM containing 10% non-heat-inactivated FBS
and penicillin/streptomycin. Cell suspension was filtered through
a 70 mm nylon cell strainer (BD Falcon, Bedford, MA); red blood cells
were lysed with RBC Lysis Buffer (eBioscience, San Diego, CA).Cell 128, 71–83, January 12, 2007 ª2007 Elsevier Inc. 81
For osteoclastogenesis experiments, BM cells were plated at 4.3 3
105 cells per well in 48-well culture plates in the presence of M-CSF
and RANKL (PeproTech Inc., Rocky Hill, NJ). Alkaline-phosphatase-
positive stromal cells were fewer than 0.1% on day 5 of culture. No
osteoclast differentiation was observed without RANKL. For inhibition
of SYK kinase, 3-(1-Methyl-1H-indol-3-yl-methylene)-2-oxo-2, 3-dihy-
dro-1H-indole-5-sulfonamide (SYK inhibitor, Calbiochem, Darmstadt,
Germany) was added to BM cells cultured with M-CSF (50 ng/ml)
and RANKL (50 ng/ml). After 5 days, TRAP-positive cells with more
than three nuclei were counted as osteoclasts.
For experiments with BM-derived macrophages, BM cells were
cultured with a-MEM and 10%FBS for 2–12 hr, then nonadherent cells
were cultured for 3 days in the presence of 50 ng/ml M-CSF. For mea-
surements of TNF-a protein and transcript levels following stimulation
with M-CSF, cells were starved for 2 hr in medium containing 0.1%
FBS without M-CSF and with or without 10 mM U0126 (Cell Signaling
Technology, Inc., Beverly, MA).
To block NF-kB signaling, nonadherent BM cells cultured for 3 days
with 50 ng/ml M-CSF were harvested in M-CSF-free a-MEM contain-
ing 10%FBS and replated at a concentration of 33 105 cells per well in
96-well plates. The cells were incubated for 2 hr with or without 20 mM
NEMO-binding domain peptide in a-MEM containing 10% FBS before
being restimulated with 50 ng/ml M-CSF for an additional 36 hr. The
sequence of the NEMO-binding domain peptide was drqikiwfqnrrmk
wkk-TALDWSWLQTE (Jimi et al., 2004).
Western Blotting
For studies of long-term effects of RANKL on osteoclastogenesis,
5.53 106 BM cells were cultured withM-CSF (50 ng/ml) in 6 cm culture
plates for 2 days, then stimulated with RANKL (50 ng/ml) for an addi-
tional 3 days. To study short-term effects of RANKL stimulation of
osteoclastogenesis, 5.5 3 106 BM cells were cultured with M-CSF
(50 ng/ml) in 6 cm culture plates for 3 days, starved for 6 hr with 1%
FBS and 1 ng/ml M-CSF, and then stimulated by RANKL (50 ng/ml).
For studying effects of M-CSF stimulation of macrophages, 4.0 3
106 nonadherent BM cells were cultured with M-CSF (50 ng/ml) in
6 cm culture plates for 3 days, starved for 2 hr with M-CSF-free
medium containing 0.1% FBS, and then stimulated by M-CSF
(50 ng/ml). For determination of SH3BP2 in mutant tissues, spleens
were snap frozen in liquid nitrogen and homogenized in lysis buffer.
Cell lysates (for details, see Supplemental Data) were used for
western blotting. Bands were detected using SuperSignal West Pico
or Femto Chemiluminescent Substrate (Pierce Biotechnology Inc.,
Rockford, IL).
Peritoneal Macrophage Isolation
After euthanasia, 6 ml of DMEM were injected into peritoneal cavity
and aspirated back. Peritoneal cells were pelleted by centrifugation,
and 1 3 105 cells in 200 ml DMEM were plated in each well of a
96-well culture plate then incubated at 37C for 1 hr. Adherent macro-
phages were further cultured in DMEM (10% FBS; for details, see Sup-
plemental Data).
Flow Cytometry
Marrow cells were harvested from tibia and femur of 10-week-old
mice. After RBC lysis, cells were stained with anti-CD11b (PE, clone:
M1/70) antibodies and analyzed using FACSCalibur (BD Biosciences,
San Jose, CA). Peritoneal cells were harvested from 6- to 10-week-old
mice, stained with anti-CD11b (PE, clone: M1/70) and anti-F4/80
(PE-Cy5, clone: BM8) antibodies; permeabilized cells were stained
with anti-TNF-a (FITC, clone: MP6-XT22) antibody and analyzed. All
antibodies for FACS were from eBiosciences (San Diego, CA).
Retroviral Infection of BM-Derived Macrophages
HA-tagged wild-type and P416R Sh3bp2 cDNAs were subcloned into
pMXs-IG vector (a gift from Prof. T. Kitamura). Transfection into Plat-
E packaging cells was performed using FuGENE 6 (Roche, Alameda,82 Cell 128, 71–83, January 12, 2007 ª2007 Elsevier Inc.CA). After 48 hr of transfection, supernatants were collected and used
for infection. BMcells were culturedwithM-CSF (50 ng/ml) for 48 hr fol-
lowedby 24hr inmediumcontaining retrovirus andpolybrene (8mg/ml).
Infection efficiency was normalized based on GFP expression. After
infection, cells were stimulated with RANKL (50 ng/ml) for additional
72 hr, stained for TRAP (Sigma), or lysed for western blotting.
Fetal Liver Cell Transplantation
Fetal livers (E15.5) were dissociated in 10% FBS RPMI. After genotyp-
ing, 1 3 107 viable cells were injected intravenously into sublethally
(250 cGy, 137Cesium source) g-irradiated 4- to 5-week-old Rag1 null
mice. After 6 weeks, successful transplantation was confirmed by
the presence of abTCR- and B220-positive cells in peripheral blood.
In recipient mice, the proportion of homozygous donor cells in
M-CSF-dependent osteoclast precursor cells was about 70% as
determined by semiquantitative genomic PCR.
Real-Time PCR for TNF-a Transcripts
Total RNAs were extracted using Trizol, and cDNAs were synthesized
by Superscript II (Invitrogen). Real-time PCR was carried out with ABI
PRISM 7900HT Sequence Detection System (Applied Biosystems)
using TaqMan PCR kit protocol (for details, see Supplemental Data).
Expression levels of TNF-a transcripts were normalized to the number
of 106 GAPDH transcripts.
Supplemental Data
Supplemental data include Supplemental Experimental Procedures
and four figures and can be found with this article online at http://
www.cell.com/cgi/content/full/128/1/71/DC1/.
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